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Abstract
Background: Prostate tumor heterogeneity is a major factor in disease management. Heterogeneity could be due
to multiple cancer cell types with distinct gene expression. Of clinical importance is the so-called cancer stem cell
type. Cell type-specific transcriptomes are used to examine lineage relationship among cancer cell types and their
expression similarity to normal cell types including stem/progenitor cells.
Methods: Transcriptomes were determined by Affymetrix DNA array analysis for the following cell types. Putative
prostate progenitor cell populations were characterized and isolated by expression of the membrane transporter
ABCG2. Stem cells were represented by embryonic stem and embryonal carcinoma cells. The cancer cell types
were Gleason pattern 3 (glandular histomorphology) and pattern 4 (aglandular) sorted from primary tumors,
cultured prostate cancer cell lines originally established from metastatic lesions, xenografts LuCaP 35
(adenocarcinoma phenotype) and LuCaP 49 (neuroendocrine/small cell carcinoma) grown in mice. No detectable
gene expression differences were detected among serial passages of the LuCaP xenografts.
Results: Based on transcriptomes, the different cancer cell types could be clustered into a luminal-like grouping
and a non-luminal-like (also not basal-like) grouping. The non-luminal-like types showed expression more similar to
that of stem/progenitor cells than the luminal-like types. However, none showed expression of stem cell genes
known to maintain stemness.
Conclusions: Non-luminal-like types are all representatives of aggressive disease, and this could be attributed to
the similarity in overall gene expression to stem and progenitor cell types.
Background
Tumor heterogeneity is a major hurdle in effective treat-
ment of the disease. This heterogeneity could be due to
multiple cancer cell types with distinct gene expression.
How do these cell types arise? The cancer stem cell
hypothesis states that tumors are propagated by cancer
cells with stem-cell characteristics, and that tumor het-
erogeneity results from differentiation of these stem-like
cells. Tumors from several tissue types have been found
to contain specific populations of tumorigenic and non-
tumorigenic cells. Breast tumor formation can be
initiated by a small number of tumorigenic cells charac-
terized as CD44
+CD24
lo/-, while non-tumorigenic cells
are CD44
-CD24
+. The latter could be generated from
the former during tumor growth [1]. Tumorigenicity is
assayed by xenograft implantation and tumor expansion
in immune-compromised hosts. In leukemia, tumori-
g e n i cc e l l ss h a r eap h e n o t y p eo fC D 3 4
+CD38
- with nor-
mal hematopoietic stem cells [2]. Tumorigenic or cancer
stem cells that are typed CD133
+CD44
+CD49b
+CD29
+
have also been reported for prostate tumors [3]. To
date, these cluster designation (CD) cell surface mole-
cules are the principal markers used to qualify these
tumorigenic cells as cancer stem cells, and the fact these
cells can apparently undergo differentiation to produce
other types.
Prostate cancer is a common cancer in men in the Wes-
tern countries, and the second leading cause of cancer
mortality [4]. Why the human prostate is prone to devel-
oping cancer and what the molecular mechanism of the
disease process remain unanswered. In prostate develop-
ment, epithelial differentiation is mediated by stromal
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any medium, provided the original work is properly cited.mesenchyme induction of stem cells [5]. Thus, epithelial
elements containing stem/progenitor cells isolated from
either the prostate or the bladder can be induced by pro-
static stromal cells to produce only prostate-like structures
[6]. Presumably, bladder stromal cells would induce blad-
der-like structures instead if that experiment was done.
This induction could be defective in cancer due to abnor-
mal gene expression by the tumor-associated stromal cells
[7]. The lack of appropriate stromal signaling may lead to
abnormal epithelial differentiation giving rise to diseases
like cancer. The alternative is that a cancer stem cell
emerges after accumulating enough critical somatic DNA
mutations over time, and this then differentiates into can-
cer epithelial cells (and perhaps the cancer-associated stro-
mal cells as well).
In this report, we used cell type-specific transcrip-
tomes obtained in our lab to examine possible lineage
relationship between prostate cancer cell types and nor-
mal cell types including that of stem/progenitor. Our
goal was to determine the extent of stem-cell gene
expression not only of the CD molecules but also of all
others in cancer, and to see how this gene expression
was correlated with tumor biology. The cancer cell types
included prostate cancer cell lines LNCaP, C4-2, CL1,
PC3, DU145, tumor xenografts LuCaP 35 and LuCaP
49, CD26
+ Gleason pattern 3 (G3) and pattern 4 (G4)
cancer cells isolated from primary tumors [8]. G3 cancer
cells are typical of well-differentiated tumors showing
glandular histoarchitecture, while G4 cancer cells are of
tumors without glandular differentiation [9]. Tumors
with a significant component of G4 are associated with
poor outcome. The in vitro cultured cell lines were
established from metastasis: lymph node for LNCaP,
bone for PC3 and brain for DU145 [10]. C4-2 and CL1
were derived from LNCaP through selection in castrated
animals and androgen-depleted growth media, respec-
tively. The in vivo maintained LuCaP 35 was derived
from a lymph node metastasis and shows features of a
prostate-specific antigen (PSA/KLK3)-producing adeno-
carcinoma [11]. LuCaP 49 was established from an
omentum metastasis and shows features of a PSA non-
producing neuroendocrine small cell carcinoma [12].
Thus, a wide spectrum of this disease is covered by
these different cell types. In this analysis, stem cell types
were represented by the embryonal carcinoma (EC) cell
line NCCIT (hyperdiploid, established from a nonsemi-
nomatous germ cell tumor) [13], and embryonic stem
(ES) cell line H1 (WA01, karyotype 46, XY) [14]. EC
and ES cells have been shown to have very similar gene
expression [15], and are stained positive for stem cell-
specific alkaline phosphatase. We have reported that
NCCIT could undergo differentiation with loss of stem
cell markers, growth retardation, and altered morphol-
ogy under the influence of either prostate or bladder
stromal cells in co-culture [16]. Non-cancer cell types
were represented by sorted CD26
+ luminal epithelial,
CD104
+ basal epithelial, CD49a
+ stromal smooth mus-
cle, CD31
+ endothelial cells [17], and prostate cell popu-
lations identified and isolated by their expression of the
transmembrane ATP-binding cassette transporter
ABCG2 [18]. Isolation of ABCG2
+ cells was done either
by the use of anti-ABCG2/CDw338 monoclonal in mag-
netic cell sorting (MACS) or via flow cytometry of side
populations. Side populations are due to the ability of
ABCG2 to efflux a DNA dye (which ABCG2-negative
cells in the main population cannot), and bone marrow
side populations are enriched for marrow graft repopu-
lating stem cells. The ABCG2
+ cells were used to repre-
sent adult organ progenitor cells of the prostate whereas
ES and EC cells were of germ cells. All transcriptome
datasets are available on our public database UESC [19],
which is also incorporated in the NCI-EDRN (Early
Detection Research Network) website. Data quality of
Affymetrix-derived transcriptomes was assessed for cor-
respondence between array hybridization signals of CD
genes and CD immunostaining results [20]. In general,
there was a good fit between the two data types, i.e.,
immunostained cell types showed array hybridization
signals for the corresponding CD genes. For lineage
relationship, we employed a principal components ana-
lysis of array datasets to characterize the relatedness
between cell types as defined by their transcriptomes, i.
e., the entire repertoire of expressed genes.
Materials and methods
Prostate cancer cell lines and xenografts
Prostate cancer cell lines CL1 (and its subclones CL1.1
and CL1.31) [21,22], DU145 and PC3 were cultured and
harvested for array analysis as described in our previous
report on differential gene expression between LNCaP
and C4-2 [23]. The LuCaP series of xenografts were
generated in our department from surgical specimens
and donor necropsies implanted subcutaneously in mice
[24]. All specimens were obtained after informed con-
sent and collected using protocols approved by the
Institutional Review Board and Human Subject Division
at the University of Washington. The tumors were seri-
ally passaged in mice and harvested for analysis. Sam-
ples of LuCaP 35 and LuCaP 49 at five different
passages were analyzed by DNA arrays to examine if
gene expression was stable over time. NCCIT cells were
cultured in RPMI1640 media [16], and H1 cells at pas-
sage 70 were cultured as previously described [14] either
with mouse embryonic fibroblast (MEF) feeder or in
MEF-conditioned media, and for the last two passages
before harvest in TeSR2 media (STEMCELL Technolo-
gies, Vancouver, Canada) on growth factor-reduced
Matrigel (BD Biosciences, San Jose, CA).
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Quality and concentration of RNA prepared from cells
or xenografts were determined by Agilent 2100 Bioana-
lyzer and RNA Labchip (Agilent Technologies, Santa
Clara, CA). Human Genome U133 Plus 2.0 GeneChips
(Affymetrix, Santa Clara, CA) were used for expression
profiling. The U133 array contained probesets represent-
ing 54,675 genes, splice variants, and ESTs. The Gene-
Chips were prepared, hybridized, and scanned according
to the protocols provided by Affymetrix (P/N 702232
Rev. 2) [23]. RNA prepared from LuCaP 35, LuCaP 49
and H1 were reverse transcribed with poly (dT)/T7 pro-
moter primer, and the cDNA was made double-
stranded. In vitro transcription was performed with bio-
tinylated ribonucleotides, and the biotin-labeled cRNA
was hybridized to the GeneChips. The chips were
washed and stained with streptavidin-PE using FS-450
fluidics station (Affymetrix). Data was collected with
Affymetrix GeneChip Scanner 3000. All five samplings
of each xenograft at different passages were analyzed.
Prostate cell type-specific transcriptomes
Previously determined cell type-specific transcriptomes
were downloaded from UESC [19]. The sorted cell
populations were isolated from prostate tissue speci-
mens obtained from patients undergoing radical prosta-
tectomy [8,17,18]. Both cancer and non-cancer samples
were digested by collagenase for cell isolation by MACS.
Transcriptomes were obtained for CD104
+ basal, CD26
+
luminal, CD49a
+ stromal, CD31
+ endothelial, ABCG2
+
(5D3) or side-population (SP) progenitor, CD26
+ cancer
cells of Gleason 3+3 (G3) and 4+4 (G4) primary tumors.
Transcriptomes were also available for the prostate can-
cer cell lines LNCaP, C4-2, CL1, DU145, PC3 as well as
those of NCCIT and H1.
Computational analysis of datasets
For differential gene expression, datasets were analyzed
by HTself, a self-self based statistical method for low
replication microarray data, specifically those obtained
from isolated cancer cell types [8]. To apply this
method, all possible combination of pair-wise compari-
sons among experiments were taken to create sets of
ratios. Gene expression level was defined as the normal-
ized and summarized intensities of each GeneChip pro-
beset, and was presented as its logarithmic value: X =
log2(Normalized intensity). This step was carried out
using the standard robust multi-array average (RMA)
method [25], implemented in the analysis pipeline
SBEAMS [26]. The strength of differential expression
between any pair of experiments was estimated by Mi =
log2(ratio) = Xi-Xa,w h e r ea represented one particular
cell type and i represented each given cell type in the
set. A probeset was considered significantly differentially
expressed if at least 80% of its log-ratio combinations
were outside the 99.9% credibility intensity-dependent
cutoff. Moreover, an average greater than 8-fold differ-
ence in expression level was chosen.
In principal components analysis (PCA) of the tran-
scriptome datasets, a gene expression subspace was
obtained that highlighted the principal sources of varia-
bility among transcriptomes of the different prostate cell
types. This space was created with transcriptomes of the
four cell types isolated from the prostate: luminal L, basal
B, stromal S and endothelial E. A rotation matrix was
obtained by using averages of XL, XB, XS,a n dXE,a n d
these were plotted as projections on the principal compo-
nents graph (see Supplemental File 1, http://labpib.open-
wetware.org/PCA.html). The other transcriptomes were
then projected into this PCA-generated subspace, which
could be rotated freely to visualize spatial separation of
the individual datapoints denoting the cell types. The fol-
lowing datasets were thus analyzed: CD26
+ luminal,
CD49a
+ stromal, CD104
+ basal, CD31
+ endothelial,
ABCG2
+ progenitor (5D3), SP, CD26
+ G3 cancer, CD26
+
G4 cancer, LNCaP, C4-2, CL1 (and subclones), DU145,
PC3, LuCaP35, LuCaP49, NCCIT and H1.
Results
Relatedness between prostate progenitor cells and stem
cells
The prostate SP was isolated due to its slower uptake of
Hoechst 33342 due to ABCG2. SP was collected from
cells pre-selected by MACS using anti-CD44 since
ABCG2
+ cells were detected in the CD44
+ basal epithe-
lium of the prostate. They constituted a minor popula-
tion (< 1%) and differed from ABGC2
+ endothelial cells
of capillaries by expression of the basal marker CD138/
SDC1 [18]. In addition to SP, the ABCG2
+ cells were
sorted from sizable benign tissue specimens using the
ABCG2 antibody clone 5D3, and labeled as 5D3 popula-
tions [18]. Figure 1A shows a PCA subspace defined by
the transcriptomes of basal, luminal, stromal, and
endothelial. These four differentiated cell types are dis-
tinct in gene expression, and are widely separated in
this three dimensional plot. The distance between any
two datapoints is a measure of the extent of differential
gene expression. Transcriptomes of the SP and 5D3
cells were then projected into this “human prostate”
PCA subspace plus the transcriptome of NCCIT used as
that of human pluripotent stem cells.
First, a majority of 5D3 cell sorts were clustering near
the endothelial cells. In our sorting scheme, CD31/
PECAM1 antibody was first used as a means to purge
CD31
+ABCG2
+ endothelial cells in the tissue digests
before sorting by the 5D3 antibody. However, significant
amounts of any residual endothelial cells in the resul-
tant, presumably CD31
-ABCG2
+,p o p u l a t i o n sw o u l d
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Figure 1 Principal components analysis of prostate ABCG2
+ cells. A: This human prostate PCA space is keyed on the transcriptomes of B, L,
S, and E cells. Stem cell transcriptome is represented by that of NCCIT. Putative progenitor cells sorted from the prostate by antibody to ABGC2
(clone 5D3) or in SP are shown. Many 5D3 sorts (red cubes) are found to cluster near E except for that derived from specimen 04-126. This and
two SPs are positioned nearer the NCCIT. B: The expression levels of CD133 and CD31 in 04-126, other 5D3 sorts (labeled as “5D3”), endothelial
sorts (labeled as CD31+) and SP are indicated by array signal values on a gray scale in the data query display. The histograms below show the
same query output. Note the different expression magnitude scales on the y-axis for the two genes.
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progenitor cells. Nevertheless, one particular 5D3 popu-
lation obtained from specimen 04-126, plotted closer to
NCCIT apart from the other 5D3 sorts, might represent
a progenitor population with less endothelial contamina-
tion. The array signal intensity value for the CD31 gene
i n0 4 - 1 2 6w a s1 2 3 5c o m p a r e dt o5 3 3 6( a v e r a g eo ff i v e )
for the other 5D3 populations, 2719 (average of five) for
the CD31-sorted endothelial populations, and 1049
(average of two) for SP. The signal value for CD133 in
04-126 was 113 compared to 40 for the other 5D3 sorts
and 61 for the CD31 sorts, and 110 for SP (Figure 1B).
For the expression of these two markers, the 5D3 of 04-
126 and SP were similar, and both populations (isolated
by different methodologies) were found plotted near the
EC cells. Some of the differences could be attributed to
genes involved in cell proliferation since the EC cells
were harvested from in vitro cultures. Second, although
ABCG2
+ cells and basal cells share CD specificities (e.g.,
CD44, CD49f, CD138), the 04-126/SP cluster was distal
from the ABCG2
- basal B signifying that the overall
gene expression was significantly different between these
cell types. Based on this transcriptome analysis, basal
cells did not appear to represent a possible progenitor
population of secretory cells, which was postulated by
some investigators (see ref. [27]), by showing less gene
expression overlap with EC cells than the ABCG2
+ cells.
Dataset comparison was carried out between SP, 5D3
(04-126) and EC, ES. The expression pattern of several
g e n e si nt h e s ep o p u l a t i o n si ss h o w ni nF i g u r e2 A .F i r s t ,
note the similarity between EC and ES cells in the expres-
sion levels of stem cell markers SOX2, LIN28, NANOG,
POU5F1/LOC642559, TDGF1 (CRIPTO) and PROM1
(CD133). In addition, stem cell marker could also be con-
sidered for CD9 [28] and THY1 (CD90) [29]. Figure 2B
shows the proximity of ES (H1) and EC (NCCIT) in gene
expression by PCA. For POU5F1 (OCT4), two Affymetrix
probesets (235842_at, 238997_at) produced no signal
while two others, LOC642559 (210265_x_at) and
LOC645682 (210905_x_at), gave strong signals. Both SP
and 5D3 cells showed low expression levels of these stem
cell genes. NCCIT was negative for ABCG2 expression
[18], so were the ES cells in contrast to SP and 5D3, which
were obtained based on ABCG2 expression. Despite these
differences, the overall gene expression of the 5D3 and SP
populations was more similar to that of stem cells than to
any of the differentiated cell types (i.e., L, S, B, E) as indi-
cated by PCA. There were 13,413 genes with signal inten-
sity values > 100 expressed in common by all three (>
80%); 15,899 between ES and EC; 14,404 between ES and
5D3; 14,913 between EC and 5D3. The common pool for
SP and ES/EC was 13,122, and 16,300 between 5D3 and
SP. Accordingly, the PCA display could be viewed as a cell
differentiation space in which the undifferentiated stem/
progenitor cells appeared to occupy a more interior posi-
tion and the differentiated cell types were positioned
towards the periphery. Relatedness between cell types was
indicated by the separation of the datapoints. Thus, the
gene expression difference between the epithelial cell types
(luminal and basal) was almost as large as that between
epithelial and stromal cells. These three prostate cell types
have their individual complement of CD molecules [30].
2. Prostate cancer cell types as defined by transcriptome
The cancer cell types analyzed were cells sorted from
tumor tissue specimens, cancer cell lines cultured in
vitro, and xenografts grown in vivo. Array results for the
LuCaP xenografts at various passages showed minimal
gene expression changes during serial transplantation in
mice, from p64 to p99 for LuCaP 35 and p40 to p59 for
LuCaP 49. There was no evidence in enrichment of CD
stem cell markers over time, e.g., CD44 in LuCaP 35
(Figure 3). These tumor cells appeared to maintain their
expression profile during long-term growth as indicated
by the relative array signal levels of the genes in Figure
3. Dataset query confirmed that LuCaP 49 was negative
for androgen receptor (AR), KLK3, whereas LuCaP 35
was positive for these two markers. Furthermore, data
query showed that LuCaP 49 was CD57
+ (B3GAT1; a
marker associated with cells showing neuroendocrine
differentiation), CD44
-,C D 1 0 7 b
+ (LAMP2, expressed by
many prostate cancer cell types [31]), CD10
-,C D 1 3 3
+;
LuCaP 35 was CD57
-,C D 4 4
-, CD107b
+,C D 1 0
+, CD133
-
. These CD reactivities had been verified by flow cyto-
metry analysis and immunostaining [12,32].
The PCA plot shown in Figure 4A incorporated the
transcriptomes of LNCaP, C4-2, CL1, PC3, DU145,
LuCaP 35, LuCaP 49, G3 cancer (specimen 05-179) and
G4 cancer (specimen 08-032), plus NCCIT as a cancer
stem cell type. For the cell lines, C4-2 was derived from
LNCaP, and their transcriptomes have been shown by
us to be very similar with 90% of the genes detected
[23], and this was indicated by PCA. One notable differ-
ence was CD26 (Table 1). A small CD26
+ population
could be detected and expanded after CD26 sorting
from overall CD26
- LNCaP cultures. This subpopulation
could be related to the CD26
+ C4-2 [32]. This result
suggested that CD subpopulations could also exist in
the LuCaP tumors and others. CL1 was also derived
from LNCaP, and several clones (e.g., CL1.1, CL1.31)
were further obtained showing different growth charac-
teristics in vivo and in vitro. The CL1s were plotted in
the vicinity of PC3 and DU145. Therefore, these three
cell lines were scored very similar in overall gene
expression, which was supported by their CD phenotype
(Table 1). The table shows that none of the cancer cell
types listed was positive for both CD44 and CD133,
markers most often cited as associated with cancer stem
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-CD133
- LuCaP 35 could be propagated
in mice equally successfully as the CD44
-CD133
+ LuCaP
49, although whether small numbers of these tumor
cells could form tumors has not been tested. LuCaP 35,
like LNCaP, was derived from a lymph node metastasis.
Thus, not surprisingly, the CD10
+ LNCaP, C4-2, and
LuCaP 35 were positioned near each other; LuCaP 35
and LNCaP were not exactly alike. LuCaP 49, being a
neuroendocrine tumor type, was quite unlike any other
in PCA. The G4 was also unlike any other. For the
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Figure 2 Gene expression comparison of ABCG2
+ cells and stem cells. A: Differential expression of selected genes between 5D3 (04-126), SP
and ES (H1) and EC (NCCIT) cells as obtained from dataset query is shown. B: PCA plot of H1 and NCCIT shows the close relatedness between
these two cell types.
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Figure 3 LuCaP xenograft gene expression. Displayed are the expression patterns of selected genes (listed in the first column) in the two
LuCaP xenografts with individual datasets identified by their passage numbers p.
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Figure 4 PCA of prostate cancer cell types. A: Transcriptomes of prostate primary cancer G3, G4, cell lines LNCaP, C4-2, CL1, DU145, PC3,
xenografts LuCaP 35, LuCaP 49 are projected into the space defined by B-L-S-E. The CL1 data point also contains transcriptomes from CL1
subclones. B: Panel A shows grouping of the so-called luminal-like cancer cell types, while panel B shows grouping of the non-luminal-like
cancer cell types in a different viewing aspect.
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Page 7 of 13primary tumor cells, G3 was plotted closer to luminal L
than G4, not unexpected since tumors with G4 cells do
not display a glandular morphology. The small separa-
tion for G3 and L amounted to ~200 genes with > 8-
fold difference in expression between the two [8]. The
G3 cancer could be described as luminal-like. Luminal-
like is here intended to mean that the cancer transcrip-
tome is like that of luminal cells, i.e., luminal and G3
cells share many genes. In contrast, G4 and luminal
cells share far fewer genes.
In PCA, a subgrouping can be seen for G3, LNCaP,
C4-2 and LuCaP 35 about L (Figure 4B, left panel).
Unlike the other three, the G3 cancer was immunotyped
as CD10 negative (luminal is positive) [8]. Again, this
analysis did not account for the genes involved in cellu-
lar proliferation, an important difference between sorted
cells and cultured cell. A second subgrouping contained
G 4 ,C L 1 ,D U 1 4 5 ,P C 3a n dL u C a P4 9( F i g u r e4 B ,r i g h t
panel). The 5D3 progenitor cell type could also be
included in it. This subgrouping was positioned closer
to the stem cell domain with CL1, PC3 and DU145
occupying a sub-domain. One may consider that G4
cells could represent a less differentiated cell type (i.e.,
closer to stem/progenitor) in the luminal epithelial line-
age than G3 cells. These less luminal-like more stem-
like cancer cell types are generally considered to have a
higher malignant potential and represent advanced dis-
eases. Outside some shared CD molecules, their overall
gene expression was quite dissimilar to basal cells as
well. The two groupings could be labeled as luminal-like
and non-luminal-like (Table 2).
3. Candidate prostate cancer stem cells
Like 5D3 and SP cells, the different non-luminal-like
prostate cancer cell types showed little expression of
Table 1 Cancer cell CD phenotyping
Cell type CD57 CD44 CD107b CD10 CD133 CD26
Luminal + - + + - +
Basal - + -/+ - - -
5D3 - + -/+ - + -
G3 + - + - - +
G4 + - + - - +
LNCaP - - + + - -
C4-2 - - + + - +
CL1 - + + - - +
DU145 - + + - - -
PC3 - + + - - +
LuCaP35 - - + + - -
LuCaP49 + - + - + -
Non-luminal-like types are all representatives of aggressive disease, and this
could be attributed to the similarity in overall gene expression to stem and
progenitor cell types.
Table 2 Prostate cells, stem cells, cancer cell lines and xenografts
Cell type Origin Characteristics AR status PSA/KLK3 status
Prostate cancer cell lines
LNCaP Lymph node metastasis Luminal Mutant AR Positive
C4-2 Derived from LNCaP through selection in castrated animals Luminal Mutant AR Positive
CL1 Derived from LNCaP through selection in androgen-depleted media Non-luminal-like Negative Negative
PC3 Bone metastasis Non-luminal-like Negative Negative
DU145 Brain metastasis Non-luminal-like Negative Negative
Xenografts
LuCaP 35 Lymph node metastasis, adenocarcinoma Luminal-like Positive Positive
LuCaP 49 Omental metastasis, small cell carcinoma Non-luminal-like Negative Negative
Cells isolated from prostate tumor specimens
G3 CD26
+ Gleason pattern 3 from primary tumor, glandular Luminal-like Positive Positive
G4 CD26
+ Gleason pattern 4 from primary tumor, aglandular Non-luminal-like Positive Positive
Stem cell lines
NCCIT Embryonal carcinoma Negative Negative
H1 Embryonic stem cell Negative Negative
Cells isolated from normal prostate tissue specimens
Luminal (L) CD26
+ luminal epithelial Positive Positive
Basal (B) CD104
+ basal epithelial Negative Negative
Stromal (S) CD49a
+ stromal Positive Negative
Endothelial (E) CD31
+ endothelial Negative Negative
Progenitor (5D3) ABCG2
+ progenitor Negative Negative
Progenitor (SP) Side population progenitor Negative Negative
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Page 8 of 13LIN28, POU5F1, NANOG, SOX2 (Figure 5A). This was
not unexpected for the luminal-like types. The cancer
cells (except LuCaP49) could be distinguished by their
expression of any one of the cancer genes AMACR,
PCA3, AGR2; their expression levels were variable.
LuCaP 49 had signals for KIT (CD117) and SOX2 in
addition to PROM1. Both 5D3 and SP also showed
expression of KIT. A single cell type with this marker
was reported to be capable of generating a prostate [33].
Figure 5B shows the expression pattern of several other
genes in these cancer cell types. Except for G4, AR
expression was minimal in the other non-luminal-like
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Figure 5 Differential gene expression among cancer cell types. A: Shown is the dataset query display of selected genes among the cell
types listed. B: Shown is the query display for seven selected genes among the non-luminal-like cancer cell types.
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Page 9 of 13types and the progenitor cells. CD44, CD49f, CD271,
CD138 are basal cell markers, and some could be
detected in the cancer cells. Note the lower expression
of CD44, by comparison, in the ES and EC cells. LuCaP
49 showed markers of neuroendocrine differentiation
CD56 and CD57, and was unique in that regard.
To gauge the frequency of CD44-positive or CD133-
positive prostate tumors, a large publicly available prostate
cancer dataset [34] was queried. The CD44
-CD133
- G3
cancer transcriptome was included for comparison (Figure
6). As can be seen, cancer expression of CD133 in these
laser-capture microdissected tumor cell specimens was
very infrequent. There was more cancer CD44 expression
in both primary tumors and metastases. Low frequencies
of tumors positive for CD133 (< 1% primary, < 4% bone
metastasis) and CD44 (< 10% metastasis) by immunostain-
ing were recently reported by Eaton et al. [35]. CD44 and
CD133 expression detected in non-cancer could be due to
basal or other cell types as total prostate RNA was used as
non-cancer in that analysis [34].
Discussion
Transcriptome comparison between prostate cancer cells
isolated from a Gleason 3+3 tumor and normal cell types
has shown relatedness between CD26
+ cancer and CD26
+
luminal cells [8]. Gleason pattern 3 cells are thought to
represent the disease at an early, well-differentiated, stage.
Several possibilities could account for the luminal-like
cancer phenotype. One, cancer cells may originate from a
human equivalent of the so-called bipotent castration-
resistant Nkx3.1-positive mouse luminal cell type (CARN)
upon loss of Pten function [36]. Two, cancer cells may
arise from a human equivalent of the Cd49f-positive
mouse basal cell type under the influence of activated Akt,
Fgf10, Erg1 and Ar. The resultant cancer cells would show
a luminal phenotype as basal cells are the progenitors of
secretory cells [37]. Three, cancer cells may result from
luminal differentiation of a neoplastic progenitor-like cell
type containing genetic alterations such as the TMPRSS2:
ERG fusion [38]. ERG1 was one of the genes with
increased expression in this G3 cancer cell type [8], and its
expression could result from a gene fusion event placing it
under the control of the androgen regulated TMPRSS2
[39]. This tumor-initiating cell type could, as postulated,
both renew and propagate tumor formation. These models
and others (e.g., the TRAMP mouse engineered with an
activatable SV40 T antigen [40]) of prostate carcinogenesis
invariably involve oncogene activation. An alternative to
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Figure 6 Prostate tumor CD44 and CD133 expression. Dataset identities in the histograms are indicated on the x-axis. Red is that of 05-179
CD26
+ G3 cancer cells, which shows absent CD44 and CD133 expression.
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Page 10 of 13this involves cell-cell signaling. Cancer differentiation takes
place because tumor-associated stromal cells are function-
ally defective due to their down-regulated expression of
certain organ-restricted genes and genes in smooth muscle
cell differentiation [7]. Stromal cells in normal tissue are
characterized as smooth muscle cells. Organ-specific stro-
mal induction of epithelial differentiation could be attribu-
ted to the genes differentially expressed between prostate
and, say, bladder stromal cells. Stem/progenitor cells dif-
ferentiate in response to the cues provided by the stromal
elements. In this model, a prostate cancer stem cell type is
not required. As these cues from tumor-associated stromal
cells are different, functional luminal differentiation can-
not be achieved resulting, for example, in the absent
expression of luminal CD10 and CD13 [8]. These mem-
brane peptidase enzymes are likely important in proces-
sing signaling protein/peptide molecules. Furthermore,
depending on the extent of stromal defect, different cancer
cell types, e.g., G3 or G4, may arise. Our study with co-
cultures of tumor-associated stromal cells and NCCIT has
shown difference in the induced gene expression of treated
NCCIT cells by these stromal cells compared to that by
normal tissue stromal cells [41].
Compared to the luminal-like types, the non-lumi-
nal-like cancer cells show less features of secretory dif-
ferentiation such as decreased expression of KLK3 and
AR, and expression of markers associated with more
primitive cell types. This is supported by the “migra-
tion” of their transcriptomes away from luminal
towards stem/progenitor. Some have gained perhaps
certain functional properties of stem cells, which was
reported for PC3 [42] and DU145 [43]. Whether they
would show response to stromal induction is yet to be
demonstrated with full transcriptome analysis. As hor-
mone influence plays an important role in prostate
cytodifferentiation [5], lack of androgen may also lead
to increased expression of progenitor cell markers
(CD133, CD44, CD117, ABCG2) in cancer cells [44].
However, based on our data analysis and data reported
in the literature, stem cell marker expression in pros-
tate cancer cells appears haphazard. Some markers, for
example, like CD49f/ITGA6 could be detected fre-
quently in metastases while others like nestin could
not [35]. Thus, there is no hard evidence for the exis-
tence of a cancer stem cell type with gene expression
similar to ES (or EC) cells in prostate cancer. Based on
overall gene expression, the closest appears to be the
trio of PC3, DU145 and CL1.
In breast cancer, a luminal-type is also known, and a
basal-type has been described to be more aggressive
than the luminal-type [45]. Although a number of basal
CD molecules are found, none of the prostate cancer
cell types show similarity to basal cells in gene
expression. Basal cells, and not luminal cells, can be cul-
tured and transformed into immortalized cell lines.
Many experiments have used these cells as a model for
normal prostate epithelial cells. They can be induced by
carcinoma-associated fibroblasts (CAF) to produce
highly malignant progeny (i.e., the non-luminal type)
[46]. The large transcriptome difference between basal
cells and stem cells as shown by PCA suggests that
basal cells are not likely to possess functional properties
of stem cells. Perhaps, the expression signature of basal-
derived cancer cells would turn out to be distinct from
the ones analyzed here.
If a cancer stem cell is not necessarily needed for
tumor development, then can a normal prostate stem
cell be programmed to produce tumor cells? The exis-
tence of a stem cell population in the prostate was
inferred from animal studies, in which castration leads
to involution of the gland, and hormone administra-
tion produces recovery [47]. Androgen removal has a
deleterious effect on the AR-positive luminal cells but
a minimal one on the AR-negative basal cells. Pro-
genitor cells that could repopulate the gland might
therefore reside in the basal epithelium. Work on the
epidermis estimated the stem cell population to be
10% of cells in the basal layer [48]. About 3% of the
basal cells show rapid adhesion to type I collagen and
have a 4-fold higher colony forming efficiency than
non-adherent cells. The adherent cells also form
glands in a mouse host when co-transplanted with
human stromal cells [49]. The ABCG2 population as
represented by the 04-126 sort could be the prostate
progenitor. These ABCG2
+CD31
-CD138
+ (and CD117
+) cells were estimated to comprise about < 1% of the
cells in the basal epithelium. The SP cells showed a
close gene expression to the ABGC2
+ cells, and were
negative for AR expression [18]. Therefore, it is possi-
ble that this cell type could give rise to either normal
or cancer cell types depending on the stromal signal-
ing. We are trying to determine if a cell line can be
established from cells isolated by the 5D3 antibody.
The technical challenge is the frequent co-isolation of
endothelial cells.
Conclusions
Transcriptomics can identify luminal-like and non-lumi-
nal-like prostate cancer cell types. A putative progenitor
cell population could be isolated by methods based on
the expression of ABCG2. The ABCG2
+ cells and the
non-luminal-like cancer cells are more similar to stem
cells in overall gene expression than the luminal-like
cancer cells. Although basal cells have been postulated
to be the progenitors of luminal cells and used as a
model of normal epithelial cells in cancer development
Pascal et al. BMC Medical Genomics 2011, 4:46
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Page 11 of 13studies, none of the cancer cell types show a basal-like
gene expression signature.
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methylacyl-CoA racemase; AGR2: anterior gradient 2; AR: androgen receptor;
B: prostate basal epithelial cells; B3GAT1 (CD57): β-1,3-glucuronyltransferase
1; CD: cluster designation; CD26/DPP4: dipeptidyl peptidase 4; E: endothelial
cells of blood capillaries; EC: embryonal carcinoma; ERG1: early growth
response 1; ES: embryonic stem; EST: expressed sequence tag; G3: Gleason
pattern 3; G4: Gleason pattern 4; ITGA6/CD49f: integrin α6; KIT/CD117: v-kit
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; L: prostate
luminal epithelial cells; LAMP2/CD107b: lysosomal-associated membrane
protein 2; LIN28: lin-28 homolog (C. elegans); MACS: magnetic cell sorting;
MME/CD10: membrane metallo-endopeptidase; NANOG: Nanog homeobox;
NCAM1/CD56: neural cell adhesion molecule 1; NGFR/CD271: nerve growth
factor receptor: PCA: principal components analysis; PCA3: prostate cancer
antigen 3 (non-protein coding); PECAM1/CD31: platelet/endothelial cell
adhesion molecule; POU5F1/OCT4: POU class 5 homeobox 1; PROM1/CD133:
prominin 1; PSA/KLK3: prostate-specific antigen/kallikrein-related peptidase 3;
S: prostate stromal smooth muscle cells; SDC1/CD138: syndecan 1; SOX2:
SRY (sex determining Y)-box 2; SP: side population; TDGF1: teratocarcinoma-
derived growth factor 1; THY1/CD90: thymus cell antigen 1; TMPRSS2:
transmembrane protease, serine 2; TRAMP: transgenic adenocarcinoma of
the mouse prostate.
Acknowledgements
This research was funded by CA111244 (NCI-EDRN) and DK63630 from the
National Institutes of Health. We thank Julio C.O. Garcia for performing some
of the principal components analyses.
Author details
1Department of Urology University of Washington, Seattle, WA 98195, USA.
2Institute for Stem Cell and Regenerative Medicine, University of Washington,
Seattle, WA 98195, USA.
3University of Pittsburgh Medical Center,
Department of Urology, Pittsburgh, PA 15232, USA.
4Genetics Department,
University of São Paulo’s Medical School at Ribeirão Preto, Brazil.
5Department of Comparative Medicine, University of Washington, Seattle,
WA 98195, USA.
6Department of Pathology, Federal University of Goias,
Goiania, Brazil.
7Department of Biochemistry, The University of Sydney,
Sydney, Australia.
Authors’ contributions
LEP and AYL designed research; LEP, AYL performed research; LEP, RZNV,
EFV, GD and AYL analyzed data; RLV provided the xenografts; CBW provided
the ES cells; LEP and AYL wrote the manuscript with contribution from the
coauthors. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 October 2010 Accepted: 23 May 2011
Published: 23 May 2011
References
1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF:
Prospective identification of tumorigenic breast cancer cells. Proc Natl
Acad Sci USA 2003, 100(7):3983-3988.
2. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nature
Medicine 1997, 3(7):730-737.
3. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 2005,
65(23):10946-10951.
4. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA: A
Cancer Journal for Clinicians 2000, 50(1):7-33.
5. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA: Normal
and abnormal development of the male urogenital tract. Role of
androgens, mesenchymal-epithelial interactions, and growth factors.
Journal of Andrology 1992, 13(6):465-475.
6. Aboseif S, El-Sakka A, Young P, Cunha G: Mesenchymal reprogramming of
adult human epithelial differentiation. Differentiation 1999, 65(2):113-118.
7. Pascal LE, Goo YA, Vencio RZ, Page LS, Chambers AA, Liebeskind ES,
Takayama TK, True LD, Liu AY: Gene expression down-regulation in CD90
+
prostate tumor-associated stromal cells involves potential organ-specific
genes. BMC Cancer 2009, 9:317.
8. Pascal LE, Vencio RZ, Page LS, Liebeskind ES, Shadle CP, Troisch P,
Marzolf B, True LD, Hood LE, Liu AY: Gene expression relationship
between prostate cancer cells of Gleason 3, 4 and normal epithelial cells
as revealed by cell type-specific transcriptomes. BMC Cancer 2009, 9:452.
9. Epstein JI: An update of the Gleason grading system. J Urol 2010,
183(2):433-440.
10. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a
compendium of old and new lines–part 1. J Urol 2005, 173(2):342-359.
11. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL:
LuCaP 35: a new model of prostate cancer progression to androgen
independence. Prostate 2003, 55(4):239-246.
12. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA,
Norwood T, Liu A, Ellis W, et al: A neuroendocrine/small cell prostate
carcinoma xenograft-LuCaP 49. Am J Pathol 2002, 161(2):705-715.
13. Damjanov I, Horvat B, Gibas Z: Retinoic acid-induced differentiation of the
developmentally pluripotent human germ cell tumor-derived cell line,
NCCIT. Lab Invest 1993, 68(2):220-232.
14. Ware CB, Nelson AM, Blau CA: A comparison of NIH-approved human ESC
lines. Stem cells 2006, 24(12):2677-2684.
15. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, Jones SB,
Brooks JD, Andrews PW, Brown PO, Thomson JA: Gene expression
patterns in human embryonic stem cells and human pluripotent germ
cell tumors. Proc Natl Acad Sci USA 2003, 100(23):13350-13355.
16. Pascal LE, Vencio RZ, Goo YA, Page LS, Shadle CP, Liu AY: Temporal
expression profiling of the effects of secreted factors from prostate
stromal cells on embryonal carcinoma stem cells. Prostate 2009,
69(12):1353-1365.
17. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY:
Transcriptomes of human prostate cells. BMC Genomics 2006, 7:92.
18. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, True LD, Liu AY:
Molecular and cellular characterization of ABCG2 in the prostate. BMC
Urol 2007, 7:6.
19. Pascal LE, Deutsch EW, Campbell DS, Korb M, True LD, Liu AY: The urologic
epithelial stem cell database (UESC) - a web tool for cell type-specific
gene expression and immunohistochemistry images of the prostate and
bladder. BMC Urol 2007, 7:19.
20. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM,
Eichner LJ, Nelson PS, Liu AY: Correlation of mRNA and protein levels: cell
type-specific gene expression of cluster designation antigens in the
prostate. BMC Genomics 2008, 9:246.
21. Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D,
McBride WH, Nguyen D, Tso CL, Belldegrun AS: Heterogeneity of
molecular targets on clonal cancer lines derived from a novel hormone-
refractory prostate cancer tumor system. Prostate 2003, 55(4):299-307.
22. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S,
Wieder JA, Zisman A, Nguyen D, Tso CL, et al: Loss of CD10 (neutral
endopeptidase) is a frequent and early event in human prostate cancer.
Prostate 2003, 55(1):71-80.
23. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL, Liu AY:
Application of Affymetrix array and Massively Parallel Signature
Sequencing for identification of genes involved in prostate cancer
progression. BMC Cancer 2005, 5:86.
24. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D,
Lange PH: Characterization of a novel androgen-sensitive, prostate-
specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin
Cancer Res 1996, 2(6):1039-1048.
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
Speed TP: Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264.
26. Marzolf B, Deutsch EW, Moss P, Campbell D, Johnson MH, Galitski T:
SBEAMS-Microarray: database software supporting genomic expression
analyses for systems biology. BMC Bioinformatics 2006, 7:286.
Pascal et al. BMC Medical Genomics 2011, 4:46
http://www.biomedcentral.com/1755-8794/4/46
Page 12 of 1327. Bonkhoff H, Remberger K: Differentiation pathways and histogenetic
aspects of normal and abnormal prostatic growth: a stem cell model.
Prostate 1996, 28(2):98-106.
28. Oka M, Tagoku K, Russell TL, Nakano Y, Hamazaki T, Meyer EM, Yokota T,
Terada N: CD9 is associated with leukemia inhibitory factor-mediated
maintenance of embryonic stem cells. Mol Biol Cell 2002, 13(4):1274-1281.
29. Dennis JE, Esterly K, Awadallah A, Parrish CR, Poynter GM, Goltry KL:
Clinical-scale expansion of a mixed population of bone-marrow-derived
stem and progenitor cells for potential use in bone-tissue regeneration.
Stem cells 2007, 25(10):2575-2582.
30. Liu AY, True LD: Characterization of prostate cell types by CD cell surface
molecules. Am J Pathol 2002, 160(1):37-43.
31. Liu AY, Roudier MP, True LD: Heterogeneity in primary and metastatic
prostate cancer as defined by cell surface CD profile. Am J Pathol 2004,
165(5):1543-1556.
32. Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL,
Belldegrun AS, Hood LE: Lineage relationship between LNCaP and
LNCaP-derived prostate cancer cell lines. Prostate 2004, 60(2):98-108.
33. Leong KG, Wang BE, Johnson L, Gao WQ: Generation of a prostate from a
single adult stem cell. Nature 2008, 456(7223):804-808.
34. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM,
Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al: Integrative
molecular concept modeling of prostate cancer progression. Nat Genet
2007, 39(1):41-51.
35. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A,
Lippitt J, Rehman I, Hamdy F, Thalman G: Evaluation of the frequency of
putative prostate cancer stem cells in primary and metastatic prostate
cancer. Prostate 2010, 70(8):875-882.
36. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV,
Hu YP, Price SM, Abate-Shen C, Shen MM: A luminal epithelial stem cell
that is a cell of origin for prostate cancer. Nature 2009,
461(7263):495-500.
37. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON: Basal
epithelial stem cells are efficient targets for prostate cancer initiation.
Proc Natl Acad Sci USA 2010, 107(6):2610-2615.
38. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA,
Rentsch CA, Schalken J, Thalmann GN, Cecchini MG: In vitro propagation
and characterization of neoplastic stem/progenitor-like cells from
human prostate cancer tissue. Prostate 2009, 69(15):1683-1693.
39. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW,
Varambally S, Cao X, Tchinda J, Kuefer R, et al: Recurrent fusion of
TMPRSS2 and ETS transcription factor genes in prostate cancer. Science
2005, 310(5748):644-648.
40. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED: The TRAMP
mouse as a model for prostate cancer. In Current protocols in immunology
Edited by: John E Coligan, et al 2001, Chapter 20(Unit 20):25.
41. Pascal LE, Ai J, Vêncio RZN, Vêncio EF, Zhou Y, Page LS, True LD, Wang Z,
Liu AY: Differential inductive signaling of prostate tumor-associated
stromal cells compared to normal tissue stromal mesenchyme cells.
Cancer Microenvironment 2011, 4(1):51-59.
42. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG: PC3 human prostate
carcinoma cell holoclones contain self-renewing tumor-initiating cells.
Cancer Res 2008, 68(6):1820-1825.
43. Wei C, Guomin W, Yujun L, Ruizhe Q: Cancer stem-like cells in human
prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biology
& Therapy 2007, 6(5):763-768.
44. Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A: Androgen
deprivation and stem cell markers in prostate cancers. International
Journal of Clinical and Experimental Pathology 2009, 3(2):128-138.
45. Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-
Jauffret E: Basal and luminal breast cancers: basic or luminous? (review).
Int J Oncol 2004, 25(2):249-258.
46. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR:
Carcinoma-associated fibroblasts direct tumor progression of initiated
human prostatic epithelium. Cancer Res 1999, 59(19):5002-5011.
47. Walensky LD, Coffey DS, Chen TH, Wu TC, Pasternack GR: A novel M(r)
32,000 nuclear phosphoprotein is selectively expressed in cells
competent for self-renewal. Cancer Res 1993, 53(19):4720-4726.
48. Slack JM: Stem cells in epithelial tissues. Science 2000,
287(5457):1431-1433.
49. Collins AT, Habib FK, Maitland NJ, Neal DE: Identification and isolation of
human prostate epithelial stem cells based on alpha(2)beta(1)-integrin
expression. Journal of Cell Science 2001, 114(Pt 21):3865-3872.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/4/46/prepub
doi:10.1186/1755-8794-4-46
Cite this article as: Pascal et al.: Lineage relationship of prostate cancer
cell types based on gene expression. BMC Medical Genomics 2011 4:46.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pascal et al. BMC Medical Genomics 2011, 4:46
http://www.biomedcentral.com/1755-8794/4/46
Page 13 of 13